Warning Letter Pilot Could Muddy Compliance Waters, Attorney Maintains
This article was originally published in The Gray Sheet
Executive Summary
FDA's proposed warning letter pilot program could have the unintended effect of making it harder for industry to interpret certain compliance-related "gray areas," Thomas Muldoon, a partner in the Chicago law firm of Burditt & Radzius, asserted Oct. 27 at the Regulatory Affairs Professionals Society annual meeting in Washington, D.C.
You may also be interested in...
CBER Warning Letter Pilot, Other Device Initiatives Recommended
FDA's Center for Biologics Evaluation and Research should adopt the Center for Device and Radiological Health's warning letter pilot program for non-blood related devices, Gen-Probe Senior Director of Regulatory Affairs Glen Freiberg told an Oct. 6 session of the Regulatory Affairs Professionals Society annual meeting in Washington, D.C.
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.